Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

Oral semaglutide did not significantly reduce disease progression in patients with early Alzheimer disease, according to results from two phase 3 trials.

The most common side effects of GLP-1 medicines are related to digestion: nausea, vomiting, diarrhoea, indigestion, stomach ...

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

There are improved cardiovascular outcomes associated with semaglutide therapy in patients with overweight or obesity without diabetes.

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

The authors conclude that early use of semaglutide may serve as an effective adjunctive strategy to mitigate the metabolic burden associated with SGAs. By intervening during the initial stages of ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an ...

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, ...